📊 ONCY Key Takeaways
Is Oncolytics Biotech Inc. (ONCY) a Good Investment?
Oncolytics Biotech faces critical financial distress with negative stockholders equity (-$3.8M), no revenue, and operating losses of $28.7M against minimal cash reserves of $5.2M, implying less than 3 months of operational runway. The company is technically insolvent on a balance sheet basis with unsustainable cash burn unless immediate capital infusion or dramatic operational restructuring occurs.
Why Buy Oncolytics Biotech Inc. Stock? ONCY Key Strengths
- Net losses improved 26.2% year-over-year, indicating operational progress and reduced burn rate trend
- Minimal capital expenditure ($6K) suggests focused early-stage pipeline without heavy infrastructure drag
- Maintained basic short-term liquidity with current ratio of 1.12x
ONCY Stock Risks: Oncolytics Biotech Inc. Investment Risks
- Negative stockholders equity of -$3.8M represents technical insolvency and threatens going concern status
- Operating cash burn of -$20.1M with only $5.2M cash provides less than 3 months of runway without new funding
- Complete absence of revenue indicates pre-commercial stage with total dependence on external capital markets
Key Metrics to Watch
- Cash depletion rate and timing of next capital raise or revenue inflection
- Quarterly cash burn trend and path to positive operating cash flow
- Clinical trial advancement and regulatory milestones
Oncolytics Biotech Inc. (ONCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Oncolytics Biotech Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ONCY Profit Margin, ROE & Profitability Analysis
ONCY vs Healthcare Sector: How Oncolytics Biotech Inc. Compares
How Oncolytics Biotech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oncolytics Biotech Inc. Stock Overvalued? ONCY Valuation Analysis 2026
Based on fundamental analysis, Oncolytics Biotech Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oncolytics Biotech Inc. Balance Sheet: ONCY Debt, Cash & Liquidity
ONCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oncolytics Biotech Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
ONCY Revenue Growth, EPS Growth & YoY Performance
Oncolytics Biotech Inc. Dividends, Buybacks & Capital Allocation
ONCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oncolytics Biotech Inc. (CIK: 0001129928)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ONCY
What is the AI rating for ONCY?
Oncolytics Biotech Inc. (ONCY) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ONCY's key strengths?
Claude: Net losses improved 26.2% year-over-year, indicating operational progress and reduced burn rate trend. Minimal capital expenditure ($6K) suggests focused early-stage pipeline without heavy infrastructure drag.
What are the risks of investing in ONCY?
Claude: Negative stockholders equity of -$3.8M represents technical insolvency and threatens going concern status. Operating cash burn of -$20.1M with only $5.2M cash provides less than 3 months of runway without new funding.
What is ONCY's revenue and growth?
Oncolytics Biotech Inc. reported revenue of N/A.
Does ONCY pay dividends?
Oncolytics Biotech Inc. does not currently pay dividends.
Where can I find ONCY SEC filings?
Official SEC filings for Oncolytics Biotech Inc. (CIK: 0001129928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ONCY's EPS?
Oncolytics Biotech Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ONCY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Oncolytics Biotech Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ONCY stock overvalued or undervalued?
Valuation metrics for ONCY: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ONCY stock in 2026?
Our dual AI analysis gives Oncolytics Biotech Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ONCY's free cash flow?
Oncolytics Biotech Inc.'s operating cash flow is $-20.1M, with capital expenditures of $6.0K.
How does ONCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 1.12 (avg: 2).